BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Le Grazie M, Biagini MR, Tarocchi M, Polvani S, Galli A. Chemotherapy for hepatocellular carcinoma: The present and the future. World J Hepatol 2017; 9(21): 907-920 [PMID: 28824742 DOI: 10.4254/wjh.v9.i21.907] [Cited by in CrossRef: 99] [Cited by in F6Publishing: 95] [Article Influence: 19.8] [Reference Citation Analysis]
Number Citing Articles
1 Qi J, Li J, Bie B, Shi M, Zhu M, Tian J, Zhu K, Sun J, Mu Y, Li Z, Guo Y. miR-3,178 contributes to the therapeutic action of baicalein against hepatocellular carcinoma cells via modulating HDAC10. Phytother Res 2022. [PMID: 36070933 DOI: 10.1002/ptr.7613] [Reference Citation Analysis]
2 Lai M, Liu Q, Chen W, Qi X, Yang J, Jiang L, Yuan M, Liu Z, He Q, Cao J, Yang B, Ghose J. Identification and Validation of Two Heterogeneous Molecular Subtypes and a Prognosis Predictive Model for Hepatocellular Carcinoma Based on Pyroptosis. Oxidative Medicine and Cellular Longevity 2022;2022:1-19. [DOI: 10.1155/2022/8346816] [Reference Citation Analysis]
3 Nour MA, Kheradmand F, Rasmi Y, Baradaran B. Alpha7 nicotinic acetylcholine receptor expression in Sorafenib-resistant Hepatocellular carcinoma cells. Med Oncol 2022;39:165. [PMID: 35972579 DOI: 10.1007/s12032-022-01745-5] [Reference Citation Analysis]
4 Becer E, Mutlu Altundag E, Başer KHC, Vatansever HS. Cytotoxic activity and antioxidant effects of Origanum onites essential oil and its two major contents, carvacrol and p -cymene on human colorectal (HCT116) and hepatocelluler carcinoma (HepG2) cell lines. Journal of Essential Oil Research. [DOI: 10.1080/10412905.2022.2107101] [Reference Citation Analysis]
5 Qin Y, Wang CJ, Ye HL, Ye GX, Wang S, Pan DB, Wang J, Shen HJ, Xu SQ. WWP2 overexpression inhibits the antitumor effects of doxorubicin in hepatocellular carcinoma. Cell Biol Int 2022. [PMID: 35880837 DOI: 10.1002/cbin.11856] [Reference Citation Analysis]
6 Lim JH, Park K, Choi KH, Kim CW, Lee JH, Weicker R, Pan C, Kim S, Park KC. Drug Discovery Using Evolutionary Similarities in Chemical Binding to Inhibit Patient-Derived Hepatocellular Carcinoma. IJMS 2022;23:7971. [DOI: 10.3390/ijms23147971] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Ma Y, Liu G, Yang J, Li X, Yang X, Fang S, Zhao B. The Efficacy of Combined Therapy of Regorafenib with Detoxicating and Stasis Softening Chinese Herbal Spleen Tonics in Mid-/Late-Stage Hepatocellular Carcinoma. Contrast Media Mol Imaging 2022;2022:9316873. [PMID: 35800233 DOI: 10.1155/2022/9316873] [Reference Citation Analysis]
8 Kim H, Lee HJ, Sim DY, Park JE, Ahn CH, Park SY, Jang E, Kim B, Kim SH. The Antitumor Effect of Cinnamaldehyde Derivative CB-PIC in Hepatocellular Carcinoma Cells via Inhibition of Pyruvate and STAT3 Signaling. Int J Mol Sci 2022;23:6461. [PMID: 35742904 DOI: 10.3390/ijms23126461] [Reference Citation Analysis]
9 Hui Y, Cui B, Wang X, Sun M, Li Y, Yang W, Guo G, Mao L, Yu Z, Fan X, Sun C. Sarcopenic obesity in liver disease: Handling both sides of the penny. Portal Hypertension & Cirrhosis 2022;1:42-56. [DOI: 10.1002/poh2.10] [Reference Citation Analysis]
10 Mohammed H, Al-mahmoud S, Arfeen M, Srivastava A, Al-raidy MZ, Ragab EA, Shehata SM, A. A. Mohammed S, Mostafa EM, El-khawaga HA, Khan RA. LC-MS Profiled Chemical Constituents, Molecular Modeling, and In vitro Bioactivity Evaluations of Suaeda vermiculata Extracts as Anti-Hepatocellular Carcinoma Preparation: Assessment of the Constituents’ Role, and Receptor Docking Feasibility Based Activity Projections. Arabian Journal of Chemistry 2022. [DOI: 10.1016/j.arabjc.2022.103950] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Freemantle N, Mollon P, Meyer T, Cheng AL, El-Khoueiry AB, Kelley RK, Baron AD, Benzaghou F, Mangeshkar M, Abou-Alfa GK. Quality of life assessment of cabozantinib in patients with advanced hepatocellular carcinoma in the CELESTIAL trial. Eur J Cancer 2022;168:91-8. [PMID: 35487183 DOI: 10.1016/j.ejca.2022.03.021] [Reference Citation Analysis]
12 Xie HN, Chen YY, Zhu GB, Han HH, Hu XL, Pan ZQ, Zang Y, Xie DH, He XP, Li J, James TD. Targeted delivery of maytansine to liver cancer cells via galactose-modified supramolecular two-dimensional glycomaterial. Chem Commun (Camb) 2022;58:5029-32. [PMID: 35373789 DOI: 10.1039/d1cc06809a] [Reference Citation Analysis]
13 Gull N, Arshad F, Naikoo GA, Hassan IU, Pedram MZ, Ahmad A, Aljabali AAA, Mishra V, Satija S, Charbe N, Negi P, Goyal R, Serrano-Aroca Á, Al Zoubi MS, El-Tanani M, Tambuwala MM. Recent Advances in Anticancer Activity of Novel Plant Extracts and Compounds from Curcuma longa in Hepatocellular Carcinoma. J Gastrointest Cancer 2022. [PMID: 35285010 DOI: 10.1007/s12029-022-00809-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
14 Mahmoud K, Swidan S, El-nabarawi M, Teaima M. Lipid based nanoparticles as a novel treatment modality for hepatocellular carcinoma: a comprehensive review on targeting and recent advances. J Nanobiotechnol 2022;20. [DOI: 10.1186/s12951-022-01309-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
15 Xu Q, Li Q, Yang Z, Huang P, Hu H, Mo Z, Qin Z, Xu Z, Chen T, Yang S. Lenvatinib and Cu2-xS nanocrystals co-encapsulated in poly(D,L-lactide-co-glycolide) for synergistic chemo-photothermal therapy against advanced hepatocellular carcinoma. J Mater Chem B 2021;9:9908-22. [PMID: 34842266 DOI: 10.1039/d1tb01808f] [Reference Citation Analysis]
16 Zhang L, Zhou L, Zhang H, Zhang Y, Li L, Xie T, Chen Y, Li X, Ling N, Dai J, Sun X, Liu J, Zhao J, Peng T, Ye M. Development of a DNA Aptamer against Multidrug-Resistant Hepatocellular Carcinoma for In Vivo Imaging. ACS Appl Mater Interfaces 2021;13:54656-64. [PMID: 34779207 DOI: 10.1021/acsami.1c12391] [Reference Citation Analysis]
17 Jung JM, Kim SH, Giang Phan VH, Thambi T, Lee DS. Therapeutic effects of boronate ester cross-linked injectable hydrogels for the treatment of hepatocellular carcinoma. Biomater Sci 2021;9:7275-86. [PMID: 34609388 DOI: 10.1039/d1bm00881a] [Reference Citation Analysis]
18 Pathak S, Sonbol MB. Second-Line Treatment Options for Hepatocellular Carcinoma: Current Landscape and Future Direction. J Hepatocell Carcinoma 2021;8:1147-58. [PMID: 34584898 DOI: 10.2147/JHC.S268314] [Reference Citation Analysis]
19 Marin JJG, Romero MR, Herraez E, Asensio M, Ortiz-Rivero S, Sanchez-Martin A, Fabris L, Briz O. Mechanisms of Pharmacoresistance in Hepatocellular Carcinoma: New Drugs but Old Problems. Semin Liver Dis 2021. [PMID: 34544160 DOI: 10.1055/s-0041-1735631] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Tawfik MM, Eissa N, Althobaiti F, Fayad E, Abu Almaaty AH. Nomad Jellyfish Rhopilema nomadica Venom Induces Apoptotic Cell Death and Cell Cycle Arrest in Human Hepatocellular Carcinoma HepG2 Cells. Molecules 2021;26:5185. [PMID: 34500621 DOI: 10.3390/molecules26175185] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
21 Gao Y, Lyu L, Feng Y, Li F, Hu Y. A review of cutting-edge therapies for hepatocellular carcinoma (HCC): Perspectives from patents. Int J Med Sci 2021;18:3066-81. [PMID: 34400877 DOI: 10.7150/ijms.59930] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
22 Alhusaini A, Cannon A, Maher SG, Reynolds JV, Lynam-Lennon N. Therapeutic Potential of PARP Inhibitors in the Treatment of Gastrointestinal Cancers. Biomedicines 2021;9:1024. [PMID: 34440228 DOI: 10.3390/biomedicines9081024] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
23 Chowdhury MMH, Salazar CJJ, Nurunnabi M. Recent advances in bionanomaterials for liver cancer diagnosis and treatment. Biomater Sci 2021;9:4821-42. [PMID: 34032223 DOI: 10.1039/d1bm00167a] [Reference Citation Analysis]
24 Özkan A, Stolley DL, Cressman ENK, McMillin M, DeMorrow S, Yankeelov TE, Rylander MN. Tumor Microenvironment Alters Chemoresistance of Hepatocellular Carcinoma Through CYP3A4 Metabolic Activity. Front Oncol 2021;11:662135. [PMID: 34262860 DOI: 10.3389/fonc.2021.662135] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
25 Mahboobnia K, Pirro M, Marini E, Grignani F, Bezsonov EE, Jamialahmadi T, Sahebkar A. PCSK9 and cancer: Rethinking the link. Biomed Pharmacother 2021;140:111758. [PMID: 34058443 DOI: 10.1016/j.biopha.2021.111758] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
26 Singh A, Shafi S, Upadhyay T, Najmi AK, Kohli K, Pottoo FH. Insights into Nanotherapeutic Strategies as an Impending Approach to Liver Cancer Treatment. Curr Top Med Chem 2020;20:1839-54. [PMID: 32579503 DOI: 10.2174/1568026620666200624161801] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Alanazi SA, Harisa GI, Badran MM, Alanazi FK, Elzayat E, Alomrani AH, Al Meanazel OT, Al Meanazel AT. Crosstalk of low density lipoprotein and liposome as a paradigm for targeting of 5-fluorouracil into hepatic cells: cytotoxicity and liver deposition. Bioengineered 2021;12:914-26. [PMID: 33678142 DOI: 10.1080/21655979.2021.1896202] [Reference Citation Analysis]
28 Zhou W, Lou W, Chen J, Ding B, Chen B, Xie H, Zhou L, Zheng S, Jiang D. AG-1024 Sensitizes Sorafenib-Resistant Hepatocellular Carcinoma Cells to Sorafenib via Enhancing G1/S Arrest. Onco Targets Ther 2021;14:1049-59. [PMID: 33623392 DOI: 10.2147/OTT.S289324] [Reference Citation Analysis]
29 El-shershaby MH, Ghiaty A, Bayoumi AH, Ahmed HEA, El-zoghbi MS, El-adl K, Abulkhair HS. 1,2,4-Triazolo[4,3- c ]quinazolines: a bioisosterism-guided approach towards the development of novel PCAF inhibitors with potential anticancer activity. New J Chem 2021;45:11136-52. [DOI: 10.1039/d1nj00710f] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
30 Yuan D, Chen Y, Li X, Li J, Zhao Y, Shen J, Du F, Kaboli PJ, Li M, Wu X, Ji H, Cho CH, Wen Q, Li W, Xiao Z, Chen B. Long Non-Coding RNAs: Potential Biomarkers and Targets for Hepatocellular Carcinoma Therapy and Diagnosis. Int J Biol Sci 2021;17:220-35. [PMID: 33390845 DOI: 10.7150/ijbs.50730] [Cited by in Crossref: 4] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
31 Zhao T, Mao L, Yu Z, Hui Y, Feng H, Wang X, Lin L, Fan X, Chen X, Wang B, Cao X, Sun C. Therapeutic potential of bicyclol in liver diseases: Lessons from a synthetic drug based on herbal derivative in traditional Chinese medicine. Int Immunopharmacol 2021;91:107308. [PMID: 33383448 DOI: 10.1016/j.intimp.2020.107308] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
32 Li Y, Han Q, Zhao H, Guo Q, Zhang J. Napabucasin Reduces Cancer Stem Cell Characteristics in Hepatocellular Carcinoma. Front Pharmacol 2020;11:597520. [PMID: 33343368 DOI: 10.3389/fphar.2020.597520] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
33 Gillman R, Lopes Floro K, Wankell M, Hebbard L. The role of DNA damage and repair in liver cancer. Biochim Biophys Acta Rev Cancer 2021;1875:188493. [PMID: 33316376 DOI: 10.1016/j.bbcan.2020.188493] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
34 Kim E, Viatour P. Hepatocellular carcinoma: old friends and new tricks. Exp Mol Med. 2020;52:1898-1907. [PMID: 33268834 DOI: 10.1038/s12276-020-00527-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 49] [Article Influence: 5.5] [Reference Citation Analysis]
35 Wang X, Zheng Y, Bao C, Zhong G, Liu S, Wiradharma N, Fan W, Yang YY, Wang X, Huang Y. Branched α-helical peptides enhanced antitumor efficacy and selectivity. Biomater Sci 2020;8:6387-94. [PMID: 33029595 DOI: 10.1039/d0bm00629g] [Reference Citation Analysis]
36 Kianamiri S, Dinari A, Sadeghizadeh M, Rezaei M, Daraei B, Bahsoun NE, Nomani A. Mitochondria-Targeted Polyamidoamine Dendrimer-Curcumin Construct for Hepatocellular Cancer Treatment. Mol Pharm 2020;17:4483-98. [PMID: 33205974 DOI: 10.1021/acs.molpharmaceut.0c00566] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
37 Shangguan AJ, Zhou K, Yang J, Eresen A, Wang B, Sun C, Pan L, Hu S, Khan AT, Mouli SK, Yaghmai V, Zhang Z. Intraprocedural Transcatheter Intraarterial Perfusion (TRIP)-MRI for Evaluation of Irreversible Electroporation Therapy Response in a Rabbit Liver Tumor Model. Clin Exp Gastroenterol 2020;13:543-53. [PMID: 33192084 DOI: 10.2147/CEG.S269163] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
38 Abyadeh M, Meyfour A, Gupta V, Zabet Moghaddam M, Fitzhenry MJ, Shahbazian S, Hosseini Salekdeh G, Mirzaei M. Recent Advances of Functional Proteomics in Gastrointestinal Cancers- a Path towards the Identification of Candidate Diagnostic, Prognostic, and Therapeutic Molecular Biomarkers. Int J Mol Sci 2020;21:E8532. [PMID: 33198323 DOI: 10.3390/ijms21228532] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
39 Redolfi Riva E, Sinibaldi E, Grillone AF, Del Turco S, Mondini A, Li T, Takeoka S, Mattoli V. Enhanced In Vitro Magnetic Cell Targeting of Doxorubicin-Loaded Magnetic Liposomes for Localized Cancer Therapy. Nanomaterials (Basel) 2020;10:E2104. [PMID: 33114052 DOI: 10.3390/nano10112104] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
40 Adenina S, Louisa M, Soetikno V, Arozal W, Wanandi SI. The Effect of Alpha Mangostin on Epithelial-Mesenchymal Transition on Human Hepatocellular Carcinoma HepG2 Cells Surviving Sorafenib via TGF-β/Smad Pathways. Adv Pharm Bull 2020;10:648-55. [PMID: 33062605 DOI: 10.34172/apb.2020.078] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
41 Zhang C, Yang M, Ericsson AC. The Potential Gut Microbiota-Mediated Treatment Options for Liver Cancer. Front Oncol 2020;10:524205. [PMID: 33163393 DOI: 10.3389/fonc.2020.524205] [Cited by in Crossref: 3] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
42 El-Daly SM, Gouhar SA, Gamal-Eldeen AM, Abdel Hamid FF, Ashour MN, Hassan NS. Synergistic Effect of α-Solanine and Cisplatin Induces Apoptosis and Enhances Cell Cycle Arrest in Human Hepatocellular Carcinoma Cells. Anticancer Agents Med Chem 2019;19:2197-210. [PMID: 31566136 DOI: 10.2174/1871520619666190930123520] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
43 Xie SC, Zhang JQ, Jiang XL, Hua YY, Xie SW, Qin YA, Yang YJ. LncRNA CRNDE facilitates epigenetic suppression of CELF2 and LATS2 to promote proliferation, migration and chemoresistance in hepatocellular carcinoma. Cell Death Dis 2020;11:676. [PMID: 32826865 DOI: 10.1038/s41419-020-02853-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
44 Chu PY, Tung SL, Tsai KW, Shen FP, Chan SH. Identification of the Novel Oncogenic Role of SAAL1 and Its Therapeutic Potential in Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E1843. [PMID: 32650537 DOI: 10.3390/cancers12071843] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
45 Malla RR, Kumari S, Kgk D, Momin S, Nagaraju GP. Nanotheranostics: Their role in hepatocellular carcinoma. Critical Reviews in Oncology/Hematology 2020;151:102968. [DOI: 10.1016/j.critrevonc.2020.102968] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
46 Parayath NN, Padmakumar S, Amiji MM. Extracellular vesicle-mediated nucleic acid transfer and reprogramming in the tumor microenvironment. Cancer Letters 2020;482:33-43. [DOI: 10.1016/j.canlet.2020.04.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
47 Rimassa L, Wörns MA. Navigating the new landscape of second-line treatment in advanced hepatocellular carcinoma. Liver Int 2020;40:1800-11. [PMID: 32432830 DOI: 10.1111/liv.14533] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
48 Abo Mansour HE, El-Batsh MM, Badawy NS, Mehanna ET, Mesbah NM, Abo-Elmatty DM. Effect of co-treatment with doxorubicin and verapamil loaded into chitosan nanoparticles on diethylnitrosamine-induced hepatocellular carcinoma in mice. Hum Exp Toxicol 2020;39:1528-44. [PMID: 32519553 DOI: 10.1177/0960327120930266] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
49 Niu Y, Tang G, Wu X, Wu C. LncRNA NEAT1 modulates sorafenib resistance in hepatocellular carcinoma through regulating the miR-149-5p/AKT1 axis. Saudi J Gastroenterol 2020. [PMID: 32461380 DOI: 10.4103/sjg.SJG_4_20] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
50 Manna D, Sarkar D. Non-Coding RNAs: Regulating Disease Progression and Therapy Resistance in Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E1243. [PMID: 32429062 DOI: 10.3390/cancers12051243] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
51 Baek SY, Hwang UW, Suk HY, Kim YW. Hemistepsin A Inhibits Cell Proliferation and Induces G0/G1-Phase Arrest, Cellular Senescence and Apoptosis Via the AMPK and p53/p21 Signals in Human Hepatocellular Carcinoma. Biomolecules 2020;10:E713. [PMID: 32375410 DOI: 10.3390/biom10050713] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
52 Di Sotto A, Di Giacomo S, Rubini E, Macone A, Gulli M, Mammola CL, Eufemi M, Mancinelli R, Mazzanti G. Modulation of STAT3 Signaling, Cell Redox Defenses and Cell Cycle Checkpoints by β-Caryophyllene in Cholangiocarcinoma Cells: Possible Mechanisms Accounting for Doxorubicin Chemosensitization and Chemoprevention. Cells 2020;9:E858. [PMID: 32252311 DOI: 10.3390/cells9040858] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
53 Pascut D, Pratama MY, Vo NVT, Masadah R, Tiribelli C. The Crosstalk between Tumor Cells and the Microenvironment in Hepatocellular Carcinoma: The Role of Exosomal microRNAs and their Clinical Implications. Cancers (Basel) 2020;12:E823. [PMID: 32235370 DOI: 10.3390/cancers12040823] [Cited by in Crossref: 13] [Cited by in F6Publishing: 20] [Article Influence: 6.5] [Reference Citation Analysis]
54 Feng YH, Tung CL, Su YC, Tsao CJ, Wu TF. Proteomic Profile of Sorafenib Resistance in Hepatocellular Carcinoma; GRP78 Expression Is Associated With Inferior Response to Sorafenib. Cancer Genomics Proteomics 2019;16:569-76. [PMID: 31659110 DOI: 10.21873/cgp.20159] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
55 Sato K, Meng F, Francis H, Wu N, Chen L, Kennedy L, Zhou T, Franchitto A, Onori P, Gaudio E, Glaser S, Alpini G. Melatonin and circadian rhythms in liver diseases: Functional roles and potential therapies. J Pineal Res 2020;68:e12639. [PMID: 32061110 DOI: 10.1111/jpi.12639] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
56 Pratama MY, Cavalletto L, Tiribelli C, Chemello L, Pascut D. Selection and validation of miR-1280 as a suitable endogenous normalizer for qRT-PCR Analysis of serum microRNA expression in Hepatocellular Carcinoma. Sci Rep 2020;10:3128. [PMID: 32081930 DOI: 10.1038/s41598-020-59682-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
57 Zhang W, Zhang J, Xu C, Zhang S, Bian S, Jiang F, Ni W, Qu L, Lu C, Ni R, Fan Y, Xiao M, Liu J. Ubiquitin-specific protease 7 is a drug-able target that promotes hepatocellular carcinoma and chemoresistance. Cancer Cell Int 2020;20:28. [PMID: 32002017 DOI: 10.1186/s12935-020-1109-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
58 Siracusano G, Tagliamonte M, Buonaguro L, Lopalco L. Cell Surface Proteins in Hepatocellular Carcinoma: From Bench to Bedside. Vaccines (Basel) 2020;8:E41. [PMID: 31991677 DOI: 10.3390/vaccines8010041] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
59 Di Sotto A, Irannejad H, Eufemi M, Mancinelli R, Abete L, Mammola CL, Altieri F, Mazzanti G, Di Giacomo S. Potentiation of Low-Dose Doxorubicin Cytotoxicity by Affecting P-Glycoprotein through Caryophyllane Sesquiterpenes in HepG2 Cells: an in Vitro and in Silico Study. Int J Mol Sci 2020;21:E633. [PMID: 31963614 DOI: 10.3390/ijms21020633] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
60 Aboismaiel MG, El-mesery M, El-karef A, El-shishtawy MM. Hesperetin upregulates Fas/FasL expression and potentiates the antitumor effect of 5-fluorouracil in rat model of hepatocellular carcinoma. Egyptian Journal of Basic and Applied Sciences 2020;7:20-34. [DOI: 10.1080/2314808x.2019.1707627] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
61 Chou LF, Chen CY, Yang WH, Chen CC, Chang JL, Leu YL, Liou MJ, Wang TH. Suppression of Hepatocellular Carcinoma Progression through FOXM1 and EMT Inhibition via Hydroxygenkwanin-Induced miR-320a Expression. Biomolecules 2019;10:E20. [PMID: 31877715 DOI: 10.3390/biom10010020] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
62 Zheng A, Chevalier N, Calderoni M, Dubuis G, Dormond O, Ziros PG, Sykiotis GP, Widmann C. CRISPR/Cas9 genome-wide screening identifies KEAP1 as a sorafenib, lenvatinib, and regorafenib sensitivity gene in hepatocellular carcinoma. Oncotarget 2019;10:7058-70. [PMID: 31903165 DOI: 10.18632/oncotarget.27361] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
63 Nair AB, Shah J, Al-Dhubiab BE, Patel SS, Morsy MA, Patel V, Chavda V, Jacob S, Sreeharsha N, Shinu P, Attimarad M, Venugopala KN. Development of Asialoglycoprotein Receptor-Targeted Nanoparticles for Selective Delivery of Gemcitabine to Hepatocellular Carcinoma. Molecules 2019;24:E4566. [PMID: 31847085 DOI: 10.3390/molecules24244566] [Cited by in Crossref: 14] [Cited by in F6Publishing: 21] [Article Influence: 4.7] [Reference Citation Analysis]
64 Ai L, Xu Z, Yang B, He Q, Luo P. Sorafenib-associated hand-foot skin reaction: practical advice on diagnosis, mechanism, prevention, and management. Expert Rev Clin Pharmacol 2019;12:1121-7. [PMID: 31679411 DOI: 10.1080/17512433.2019.1689122] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
65 Wang X, Rusin A, Walkey CJ, Lin JJ, Johnson DL. The RNA polymerase III repressor MAF1 is regulated by ubiquitin-dependent proteasome degradation and modulates cancer drug resistance and apoptosis. J Biol Chem 2019;294:19255-68. [PMID: 31645432 DOI: 10.1074/jbc.RA119.008849] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
66 Xie B, He X, Guo G, Zhang X, Li J, Liu J, Lin Y. High-throughput screening identified mitoxantrone to induce death of hepatocellular carcinoma cells with autophagy involvement. Biochem Biophys Res Commun 2020;521:232-7. [PMID: 31653348 DOI: 10.1016/j.bbrc.2019.10.114] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
67 Pratama MY, Pascut D, Massi MN, Tiribelli C. The role of microRNA in the resistance to treatment of hepatocellular carcinoma. Ann Transl Med 2019;7:577. [PMID: 31807558 DOI: 10.21037/atm.2019.09.142] [Cited by in Crossref: 15] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
68 Krause GC, Lima KG, Levorse V, Haute GV, Gassen RB, Garcia MC, Pedrazza L, Donadio MVF, Luft C, de Oliveira JR. Exenatide induces autophagy and prevents the cell regrowth in HepG2 cells. EXCLI J 2019;18:540-8. [PMID: 31611738 DOI: 10.17179/excli2019-1415] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
69 Ciccarone F, Castelli S, Ciriolo MR. Oxidative Stress-Driven Autophagy acROSs Onset and Therapeutic Outcome in Hepatocellular Carcinoma. Oxid Med Cell Longev 2019;2019:6050123. [PMID: 31205585 DOI: 10.1155/2019/6050123] [Cited by in Crossref: 15] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
70 Gans JH, Lipman J, Golowa Y, Kinkhabwala M, Kaubisch A. Hepatic Cancers Overview: Surgical and Chemotherapeutic Options, How Do Y-90 Microspheres Fit in? Seminars in Nuclear Medicine 2019;49:170-81. [DOI: 10.1053/j.semnuclmed.2019.01.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
71 Hu YL, Feng Y, Ma P, Wang F, Huang H, Guo YB, Li P, Mao QS, Xue WJ. HAX-1 promotes the migration and invasion of hepatocellular carcinoma cells through the induction of epithelial-mesenchymal transition via the NF-κB pathway. Exp Cell Res 2019;381:66-76. [PMID: 31047882 DOI: 10.1016/j.yexcr.2019.04.030] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
72 Bort A, Sánchez BG, Mateos-Gómez PA, Vara-Ciruelos D, Rodríguez-Henche N, Díaz-Laviada I. Targeting AMP-activated kinase impacts hepatocellular cancer stem cells induced by long-term treatment with sorafenib. Mol Oncol 2019;13:1311-31. [PMID: 30959553 DOI: 10.1002/1878-0261.12488] [Cited by in Crossref: 17] [Cited by in F6Publishing: 23] [Article Influence: 5.7] [Reference Citation Analysis]
73 Yang Z, Zhang J, Lin X, Wu D, Li G, Zhong C, Fang L, Jiang P, Yin L, Zhang L, Bie P, Xie CM. Inhibition of neddylation modification by MLN4924 sensitizes hepatocellular carcinoma cells to sorafenib. Oncol Rep 2019;41:3257-69. [PMID: 31002342 DOI: 10.3892/or.2019.7098] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
74 Nenu I, Breaban I, Pascalau S, Bora CN, Stefanescu H. The future is now: beyond first line systemic therapy in hepatocellular carcinoma. Transl Cancer Res 2019;8:S261-74. [PMID: 35117106 DOI: 10.21037/tcr.2018.11.23] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
75 Liu S, Du Y, Ma H, Liang Q, Zhu X, Tian J. Preclinical comparison of regorafenib and sorafenib efficacy for hepatocellular carcinoma using multimodality molecular imaging. Cancer Lett 2019;453:74-83. [PMID: 30928380 DOI: 10.1016/j.canlet.2019.03.037] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
76 Gatti P, Giorgio A, Ciracì E, Roberto I, Anglani A, Sergio S, Rizzello F, Giorgio V, Semeraro S. Hepatocellular carcinoma tumor thrombus entering the inferior vena cava treated with percutaneous RF ablation: a case report. J Ultrasound 2019;22:363-70. [PMID: 30864004 DOI: 10.1007/s40477-019-00361-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
77 Soule E, Lamsal S, Lall C, Matteo J. Eye Opener to EtOH Ablation for Juxta-Cardiac Hepatocellular Carcinoma. Gastrointest Tumors 2019;5:109-16. [PMID: 30976582 DOI: 10.1159/000495135] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
78 Kim SH, Kim MO, Kim KR. Anti-growth Effects of Imatinib and GNF5 via Regulation of Skp2 in Human Hepatocellular Carcinoma Cells. J Cancer Prev 2018;23:170-5. [PMID: 30671399 DOI: 10.15430/JCP.2018.23.4.170] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
79 Gong QZ, Xiao D, Gong GY, Xu J, Wen XD, Feng F, Qu W. EH-42: A Novel Small Molecule Induces Apoptosis and Inhibits Migration and Invasion of Human Hepatoma Cells through Suppressing STAT3 Signaling Pathway. Curr Cancer Drug Targets 2019;19:583-93. [PMID: 30585547 DOI: 10.2174/1568009619666181226094814] [Reference Citation Analysis]
80 Hu DG, Marri S, McKinnon RA, Mackenzie PI, Meech R. Deregulation of the Genes that Are Involved in Drug Absorption, Distribution, Metabolism, and Excretion in Hepatocellular Carcinoma. J Pharmacol Exp Ther 2019;368:363-81. [PMID: 30578287 DOI: 10.1124/jpet.118.255018] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 5.3] [Reference Citation Analysis]
81 Qiu Y, Dai Y, Zhang C, Yang Y, Jin M, Shan W, Shen J, Lu M, Tang Z, Ju L, Wang Y, Jiao R, Xia Y, Huang G, Yang L, Li Y, Zhang J, Wong VKW, Jiang Z. Arsenic trioxide reverses the chemoresistance in hepatocellular carcinoma: a targeted intervention of 14-3-3η/NF-κB feedback loop. J Exp Clin Cancer Res 2018;37:321. [PMID: 30572915 DOI: 10.1186/s13046-018-1005-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 4.8] [Reference Citation Analysis]
82 Kondylis V, Pasparakis M. RIP Kinases in Liver Cell Death, Inflammation and Cancer. Trends Mol Med 2019;25:47-63. [PMID: 30455045 DOI: 10.1016/j.molmed.2018.10.007] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 7.5] [Reference Citation Analysis]
83 Xie ZY, Liu MS, Zhang C, Cai PC, Xiao ZH, Wang FF. Aspirin enhances the sensitivity of hepatocellular carcinoma side population cells to doxorubicin via miR-491/ABCG2. Biosci Rep 2018;38:BSR20180854. [PMID: 30120100 DOI: 10.1042/BSR20180854] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
84 Chen YT, Xie JY, Sun Q, Mo WJ. Novel drug candidates for treating esophageal carcinoma: A study on differentially expressed genes, using connectivity mapping and molecular docking. Int J Oncol 2019;54:152-66. [PMID: 30387840 DOI: 10.3892/ijo.2018.4618] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
85 Cao F, Yin LX. miR-122 enhances sensitivity of hepatocellular carcinoma to oxaliplatin via inhibiting MDR1 by targeting Wnt/β-catenin pathway. Exp Mol Pathol 2019;106:34-43. [PMID: 30539797 DOI: 10.1016/j.yexmp.2018.10.009] [Cited by in Crossref: 18] [Cited by in F6Publishing: 26] [Article Influence: 4.5] [Reference Citation Analysis]
86 Athavale D, Chouhan S, Pandey V, Mayengbam SS, Singh S, Bhat MK. Hepatocellular carcinoma-associated hypercholesterolemia: involvement of proprotein-convertase-subtilisin-kexin type-9 (PCSK9). Cancer Metab 2018;6:16. [PMID: 30386595 DOI: 10.1186/s40170-018-0187-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
87 Kim YS, Lee YM, Oh TI, Shin DH, Kim GH, Kan SY, Kang H, Kim JH, Kim BM, Yim WJ, Lim JH. Emodin Sensitizes Hepatocellular Carcinoma Cells to the Anti-Cancer Effect of Sorafenib through Suppression of Cholesterol Metabolism. Int J Mol Sci 2018;19:E3127. [PMID: 30321984 DOI: 10.3390/ijms19103127] [Cited by in Crossref: 32] [Cited by in F6Publishing: 42] [Article Influence: 8.0] [Reference Citation Analysis]
88 Li Q, Wang W, Hu YC, Yin TT, He J. Knockdown of Ubiquitin Associated Protein 2-Like (UBAP2L) Inhibits Growth and Metastasis of Hepatocellular Carcinoma. Med Sci Monit. 2018;24:7109-7118. [PMID: 30291221 DOI: 10.12659/msm.912861] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
89 Bakhshi Aliabad H, Khanamani Falahati-Pour S, Ahmadirad H, Mohamadi M, Hajizadeh MR, Mahmoodi M. Vanadium complex: an appropriate candidate for killing hepatocellular carcinoma cancerous cells. Biometals 2018;31:981-90. [PMID: 30255365 DOI: 10.1007/s10534-018-0139-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
90 Huang D, Yuan W, Li H, Li S, Chen Z, Yang H. Identification of key pathways and biomarkers in sorafenib-resistant hepatocellular carcinoma using bioinformatics analysis. Exp Ther Med 2018;16:1850-8. [PMID: 30186410 DOI: 10.3892/etm.2018.6427] [Cited by in Crossref: 2] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
91 Liang X, Wu B, Shang H, Han X, Jing H, Sun Y, Cheng W. VTIQ evaluates antitumor effects of NET-1 siRNA by UTMD in HCC xenograft models. Oncol Lett 2018;16:2893-902. [PMID: 30127877 DOI: 10.3892/ol.2018.8994] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
92 Song P, Hai Y, Ma W, Zhao L, Wang X, Xie Q, Li Y, Wu Z, Li Y, Li H. Arsenic trioxide combined with transarterial chemoembolization for unresectable primary hepatic carcinoma: A systematic review and meta-analysis. Medicine (Baltimore) 2018;97:e0613. [PMID: 29718867 DOI: 10.1097/MD.0000000000010613] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
93 Chen CY, Chen CC, Shieh TM, Hsueh C, Wang SH, Leu YL, Lian JH, Wang TH. Corylin Suppresses Hepatocellular Carcinoma Progression via the Inhibition of Epithelial-Mesenchymal Transition, Mediated by Long Noncoding RNA GAS5. Int J Mol Sci 2018;19:E380. [PMID: 29382035 DOI: 10.3390/ijms19020380] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 6.8] [Reference Citation Analysis]
94 Guo M. Cellular senescence and liver disease: Mechanisms and therapeutic strategies. Biomed Pharmacother. 2017;96:1527-1537. [PMID: 29174037 DOI: 10.1016/j.biopha.2017.11.075] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
95 Liu J, Li Y, Yang X, Dong Y, Wu J, Chen M. Effects of ginkgol C17:1 on cisplatin-induced autophagy and apoptosis in HepG2 cells. Oncol Lett 2018;15:1021-9. [PMID: 29399162 DOI: 10.3892/ol.2017.7398] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]